OTCMKTS:CVSI - CV Sciences Stock Price, News, & Analysis

$4.17
+0.06 (+1.58 %)
(As of 06/20/2019 03:12 AM ET)
Today's Range
$4.06
Now: $4.17
$4.20
50-Day Range
$3.9950
MA: $4.64
$5.28
52-Week Range
$1.39
Now: $4.17
$9.20
Volume359,285 shs
Average Volume976,997 shs
Market Capitalization$417.78 million
P/E Ratio46.33
Dividend YieldN/A
Beta-0.2
CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. This segment provides its hemp extract products in balms, sprays, drops, capsules, gummies, and softgel forms. It also sells raw materials to various customers that produce products for resale into the market in Europe. The Specialty Pharmaceuticals segment develops cannabinoids to treat a range of medical indications. Its product candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CVSI
Previous SymbolNASDAQ:CVSI
CUSIPN/A
Phone866-290-2157

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$48.24 million
Cash Flow$0.1104 per share
Book Value$0.31 per share

Profitability

Net Income$10 million

Miscellaneous

Employees78
Market Cap$417.78 million
Next Earnings Date8/7/2019 (Estimated)
OptionableNot Optionable

Receive CVSI News and Ratings via Email

Sign-up to receive the latest news and ratings for CVSI and its competitors with MarketBeat's FREE daily newsletter.

CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions

What is CV Sciences' stock symbol?

CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."

How were CV Sciences' earnings last quarter?

CV Sciences Inc (OTCMKTS:CVSI) posted its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by $0.12. The firm earned $14.91 million during the quarter, compared to analyst estimates of $14.51 million. View CV Sciences' Earnings History.

When is CV Sciences' next earnings date?

CV Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for CV Sciences.

What price target have analysts set for CVSI?

2 equities research analysts have issued 12 month price objectives for CV Sciences' stock. Their predictions range from $8.00 to $9.00. On average, they anticipate CV Sciences' stock price to reach $8.50 in the next year. This suggests a possible upside of 103.8% from the stock's current price. View Analyst Price Targets for CV Sciences.

What is the consensus analysts' recommendation for CV Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CV Sciences.

What are Wall Street analysts saying about CV Sciences stock?

Here are some recent quotes from research analysts about CV Sciences stock:
  • 1. According to Zacks Investment Research, "CV Sciences Inc. is a life science company. Its operating segment consists of specialty pharmaceuticals and consumer products. Specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol across several therapeutic areas. Consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products. It operates primarily in San Diego, California and Las Vegas, Nevada. CV Sciences Inc. is based in Las Vegas, United States. " (6/18/2019)
  • 2. Northland Securities analysts commented, "We note inventory was $7.9M at 3/31/19, up from $7.1M at YE 2018. The toxicology report and GRAS certifications are key and a huge advantage for CVSI and we believe this will lead to a high success rate for CVSI. A few new topicals/balms are also coming as this is a category national retailers are starting with as they begin selling CBD products. Note CVS Pharmacy has 2 SKU’s a regular strength and extra strength balm. In addition, a new roll-on product is being tested and is being well received from all the retailers testing it. This product allows the customer to roll the CBD on like a deodorant stick vs. getting it all over ones fingers. Management believed a framework from the FDA would be positive and national retailers are expected to move ahead of this framework." (5/9/2019)

Has CV Sciences been receiving favorable news coverage?

News articles about CVSI stock have trended neutral on Thursday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CV Sciences earned a news impact score of 0.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for CV Sciences.

Who are some of CV Sciences' key competitors?

What other stocks do shareholders of CV Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), KushCo (KSHB), GW Pharmaceuticals PLC- (GWPH), OrganiGram (OGI), Aphria (APHA), 22nd Century Group (XXII), Charlotte's Web (CWBHF) and Medical Marijuana (MJNA).

Who are CV Sciences' key executives?

CV Sciences' management team includes the folowing people:
  • Mr. Joseph D. Dowling, CEO, Sec. & Director (Age 62)
  • Mr. Michael J. Mona III, Co-Founder, COO & Director (Age 33)
  • Mr. Joerg Grasser, CFO, Chief Accounting Officer & Director
  • Dr. Joseph Maroon, MD & Director
  • Dr. Douglas MacKay ND, Sr. VP of Scientific & Regulatory Affairs and Director

How do I buy shares of CV Sciences?

Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CV Sciences' stock price today?

One share of CVSI stock can currently be purchased for approximately $4.17.

How big of a company is CV Sciences?

CV Sciences has a market capitalization of $417.78 million and generates $48.24 million in revenue each year. The company earns $10 million in net income (profit) each year or $0.09 on an earnings per share basis. CV Sciences employs 78 workers across the globe.View Additional Information About CV Sciences.

What is CV Sciences' official website?

The official website for CV Sciences is http://www.cvsciences.com/.

How can I contact CV Sciences?

CV Sciences' mailing address is 2688 SOUTH RAINBOW BOULEVARD SUITE B, LAS VEGAS NV, 89146. The company can be reached via phone at 866-290-2157 or via email at [email protected]


MarketBeat Community Rating for CV Sciences (OTCMKTS CVSI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about CV Sciences and other stocks. Vote "Outperform" if you believe CVSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel